Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Baillie Gifford & Co. lessened its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 39.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,383,029 shares of the company's stock after selling 1,538,213 shares during the quarter. Baillie Gifford & Co. owned 1.74% of Vir Biotechnology worth $17,849,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in VIR. China Universal Asset Management Co. Ltd. grew its position in Vir Biotechnology by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 26,280 shares of the company's stock valued at $197,000 after acquiring an additional 10,294 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock worth $30,000 after purchasing an additional 2,351 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Vir Biotechnology in the third quarter worth about $56,000. Vontobel Holding Ltd. lifted its holdings in Vir Biotechnology by 27.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 57,446 shares of the company's stock valued at $430,000 after buying an additional 12,511 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. boosted its position in Vir Biotechnology by 491.7% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 18,959 shares of the company's stock valued at $169,000 after buying an additional 15,755 shares during the period. 65.32% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vir Biotechnology

In related news, Director Janet Napolitano sold 12,190 shares of the business's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the completion of the transaction, the director now owns 11,616 shares in the company, valued at $90,604.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders sold 15,940 shares of company stock valued at $127,410. 15.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on VIR. HC Wainwright reaffirmed a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Monday, November 4th. Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Friday, November 1st. Finally, Barclays decreased their target price on Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Vir Biotechnology presently has a consensus rating of "Moderate Buy" and an average target price of $36.40.

Vir Biotechnology Stock Down 2.9 %

VIR stock traded down $0.27 during trading on Wednesday, hitting $8.98. 696,896 shares of the company's stock traded hands, compared to its average volume of 1,026,851. The firm has a market capitalization of $1.24 billion, a P/E ratio of -2.32 and a beta of 0.46. Vir Biotechnology, Inc. has a 1 year low of $7.12 and a 1 year high of $13.09. The business has a fifty day simple moving average of $7.95 and a two-hundred day simple moving average of $8.96.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.05) by ($0.51). The company had revenue of $2.38 million during the quarter, compared to analysts' expectations of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company's revenue was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.22) earnings per share. On average, equities research analysts predict that Vir Biotechnology, Inc. will post -3.86 EPS for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).